Yaz, Yasmin ads must be updated to add risks of thromboembolism

by Michael J. Evans on April 19, 2010

in Consumer Protection,Dangerous Products

The Food and Drug Administration is requiring Bayer, the maker of Yaz/Yasmin birth control pills, to change its ads and promotional materials to add information about the risk of thromboembolism.  Bayer recently changed the drugs’s warning labels to include information about the risk of thromboembolism in women using Yasmin compared to contraceptives using other progestins.

In 2008, the FDA required Bayer to revise ads claiming that Yaz/Yasmin were effective for treating acne and certain menstrual disorders for which the drugs were not approved.

According to the Los Angeles Times, as of mid-February, 1100 lawsuits had been filed against Bayer accusing the drugs of causing a variety of health problems, including deep vein thrombosis (blood clots in the deep veins), strokes, heart attacks and gallbladder disease.

The drugs were already on Public Citizen’s list of drugs people shouldn’t use.

yasmin-fda-ltr-4-7-20101

Share

Previous post:

Next post: